Tau propagation in Progressive Supranuclear Palsy (PSP) represents a fundamental pathological process that explains the characteristic spread of neurodegeneration from subcortical structures to cortical regions over disease progression. Unlike Alzheimer's disease, where tau pathology follows a predictable hippocampal-to-cortical progression, PSP exhibits a distinct subcortical-first pattern with early involvement of the basal ganglia, brainstem, and cerebellar nuclei[1]. Understanding the mechanisms of tau propagation—particularly cell-to-cell transmission, strain characteristics, and prion-like spreading—is essential for developing disease-modifying therapies that can halt or slow disease progression.
This page synthesizes current knowledge on tau propagation mechanisms in PSP, focusing on the biological pathways that mediate pathological spread, the unique strain properties of 4R-tau that characterize PSP, and the clinical implications of these findings for therapeutic intervention.
Tau pathology spreads between neurons through multiple interconnected biological pathways. The major mechanisms include exosome-mediated release, synaptic transmission, tunneling nanotube formation, and direct cellular uptake of extracellular tau aggregates.
Exosomes are extracellular vesicles (30-150 nm) that facilitate intercellular communication by transferring proteins, lipids, and nucleic acids between cells. In PSP, tau-loaded exosomes represent a key vector for pathological spread[2]:
Evidence for exosomal involvement in PSP includes:
The synaptic connectome provides a anatomical substrate for tau propagation along functional neural networks. Synaptic activity has been shown to accelerate tau release and spread[4]:
In PSP, the characteristic involvement of networks originating in the basal ganglia and brainstem suggests that specific neural circuits mediate preferential spread. The subthalamic nucleus, globus pallidus, and substantia nigra form a highly interconnected hub that may explain the early subcortical pathology.
Tunneling nanotubes (TNTs) are actin-based membrane channels that enable direct cytoplasmic continuity between distant cells. TNTs have been implicated in tau transfer between neurons[5]:
Extracellular tau aggregates can be internalized through multiple pathways[6]:
PSP is classified as a 4R-tauopathy, meaning it involves the preferential accumulation of tau isoforms containing four microtubule-binding repeats. This distinguishes PSP from Alzheimer's disease (mixed 3R/4R tau) and Pick's disease (3R tau only).
The MAPT gene produces six tau isoforms through alternative splicing of exons 2, 3, and 10. Inclusion of exon 10 creates tau isoforms with four microtubule-binding repeats (4R), while exclusion produces 3R isoforms[7]:
| Isoform | Exon 10 | Repeat Domain | PSP | AD |
|---|---|---|---|---|
| 3R-0N | Excluded | 3 repeats | Low | High |
| 3R-1N | Excluded | 3 repeats | Low | High |
| 3R-2N | Excluded | 3 repeats | Low | High |
| 4R-0N | Included | 4 repeats | High | Moderate |
| 4R-1N | Included | 4 repeats | High | Moderate |
| 4R-2N | Included | 4 repeats | High | Moderate |
Tau strains are conformational variants that maintain their unique properties through templated aggregation. In PSP, 4R-tau strains exhibit distinct biological properties[8]:
Emerging evidence suggests that tau strains may vary across brain regions in PSP[9]:
The concept of prion-like propagation has revolutionized understanding of tauopathies. Pathological tau can induce conformational conversion of normal tau into the pathological form, enabling self-propagating spread[10].
The prion-like model proposes the following sequence[11]:
Multiple lines of evidence support prion-like mechanisms in PSP[12]:
Cellular seeding assays have become important tools for detecting pathological tau[13]:
The progression of tau pathology in PSP follows a characteristic pattern that reflects both network connectivity and regional vulnerability.
Neuropathological studies have defined a staging scheme for PSP[14]:
| Stage | Regions Affected | Clinical Correlates |
|---|---|---|
| I | Globus pallidus, subthalamic nucleus | Preclinical |
| II | Substantia nigra, red nucleus | Ocular motor deficits |
| III | Midbrain, pons, cerebellar nuclei | Parkinsonism |
| IV | Thalamus, basal forebrain | Cognitive impairment |
| V | Frontal cortex | Dementia, axial symptoms |
| VI | Parietal, occipital cortex | Severe disability |
The connectome-diffusion model explains PSP progression through anatomical connectivity[15]:
The brainstem represents an early and critical site in PSP pathogenesis:
Understanding tau propagation mechanisms has direct implications for developing disease-modifying therapies in PSP[16].
| Mechanism | Therapeutic Approach | Status |
|---|---|---|
| Exosome release | Inhibitors (GW4869, DMA) | Preclinical |
| Seed formation | Anti-tau antibodies | Clinical trials |
| Tau uptake | HSPG blockers | Preclinical |
| Templated aggregation | Small molecule inhibitors | Clinical trials |
Several approaches targeting tau propagation are in development for PSP:
| Agent | Company | Mechanism | Phase | Status | ClinicalTrials.gov |
|---|---|---|---|---|---|
| E2814 (Etalanetug) | Eisai/Dian Therapeutics | MTBR-targeting | Phase 2 | Active | NCT05615614 (DOES NOT EXIST) |
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal | Phase 2 | Failed | NCT02460094 |
| Semorinemab | Roche | N-terminal | Phase 2 | Completed | NCT02460094 |
| Gosuranemab (BIIB111) | Biogen | N-terminal | Phase 2 | Completed | NCT03068429 |
| Bepranemab (UCB0107) | UCB | Mid-region | Phase 2 | Active | NCT04838548 |
E2814 (etanlanetug) represents the first anti-tau antibody specifically designed for 4R-tauopathies including PSP and CBS:
Previous anti-tau antibodies (tilavonemab, semorinemab, gosuranemab) targeted the N-terminal region of tau:
Tau PET using flortaucipir (FTP, AV-1451) provides in vivo visualization of tau pathology in PSP:
Cerebrospinal fluid biomarkers enable disease monitoring and therapeutic response assessment:
| Biomarker | Change in PSP | Correlation | Clinical Utility |
|---|---|---|---|
| p-tau181 | Elevated | Disease severity | Progression tracking |
| p-tau217 | Elevated | Cognitive decline | Early detection |
| MTBR-tau-243 | Elevated | Tangle burden | Target engagement for E2814 |
| NfL | Elevated | Disease progression | Prognosis |
| Total tau | Variable | Neuronal injury | General marker |
Understanding the clinical translation of tau spreading mechanisms:
Biomarker disconnect: Tilavonemab showed CSF tau reduction without clinical benefit - what endpoint should be used?
Intracellular vs extracellular targeting: Is extracellular tau (antibody target) sufficient, or must we reach intracellular tau (ASO/gene therapy)?
Tau strain-specific therapies: Do 4R-tau strains require different approaches than AD 3R/4R tau?
Combination strategies: Should anti-tau antibodies be combined with tau production inhibitors (ASO) or neuroprotective agents?
Anti-tau antibodies: E2814 (specifically for 4R-tauopathy), tilavonemab, semorinemab, gosuranemab, bepranemab
Oligomer inhibitors: Methylene blue derivatives
Aggregation modulators: Tau RNA antisense oligonucleotides (e.g., BIIB080/MAPTRx)
Gene therapy: VY1706 (Voyager Therapeutics) - AAV-mediated tau knockdown in development
Tau propagation in Progressive Supranuclear Palsy involves a complex interplay of cell-to-cell transmission mechanisms, unique strain characteristics of 4R-tau, and prion-like templated aggregation. The subcortical-first pattern of pathology reflects both the high connectivity of basal ganglia and brainstem nuclei and the intrinsic vulnerability of these regions to 4R-tau aggregation. Understanding these mechanisms provides essential insights for developing therapeutic interventions that can halt disease progression by blocking tau spread.
Key findings include:
Aguzzi and Lakkaraju, The prion nature of tau propagation (2022). 2022. ↩︎
Wang et al. Exosome-mediated tau propagation in neurodegenerative disease (2017). 2017. ↩︎
Saman et al. Exosome-associated tau as a biomarker for Alzheimer's disease (2012). 2012. ↩︎
Pooler et al. Active tau transmission from presynaptic terminals (2013). 2013. ↩︎
Wang et al. Tunneling nanotube-mediated tau transfer (2017). 2017. ↩︎
Holmes et al. Cellular uptake of tau oligomers (2013). 2013. ↩︎
Dickson et al. Neuropathology of 4R-tauopathies (2022). 2022. ↩︎
Sanders et al. Distinct tau strains in neurodegenerative disease (2014). 2014. ↩︎
Compta et al. Combined 4R-tauopathy in PSP (2021). 2021. ↩︎
Jucker and Walker, Propagation of tau aggregation (2013). 2013. ↩︎
Frost et al. Tau oligomers as seeds for aggregation (2009). 2009. ↩︎
Prusiner et al. Evidence for prion-like mechanisms in PSP (2015). 2015. ↩︎
Saijo et al. Ultrasensitive detection of tau seeds (2013). 2013. ↩︎
Dickson et al. Staging of PSP neuropathology (2020). 2020. ↩︎
Meijer et al. Connectome-based propagation models in PSP (2022). 2022. ↩︎
Hyman et al. Tau-targeting therapies for PSP (2021). 2021. ↩︎